Base-Case Model Results: Average Per-Patient Lifetime Health and Cost Outcomes by Patient Subgroup.

DCC indicates decompensated cirrhosis; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; PR, peginterferon alfa-2a plus ribavirin; QALY, quality-adjusted life-year; TVR, telaprevir. aModeled cases of cirrhosis that developed following treatment. bDue to rounding, ICERs differ slightly from calculations using costs, life-years, and QALYs shown in this table. cOne treatment dominates another if it exhibits more QALYs at a lower total cost.